^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners

    TEST:
    Radiotron™

    Company:
    Geneseeq
    Type:
    Laboratory Developed Test
    Related tests:
    Details
    Evidence

    News

    almost2years
    Geneseeq collaborates on another minimal residual disease study in chemoradiotherapy-treated inoperable localized non-small cell lung cancer patients. (Geneseeq Press Release)
    "A recent prospective study published in the journal of Molecular Cancer led by the Chinese Academy of Medical Sciences and Geneseeq Technology Inc., demonstrated the time-dependent clinical utility of circulating tumor DNA (ctDNA) to detect the minimal residual disease (MRD) and predict prognosis in CRT-treated inoperable localized NSCLC patients."
    Clinical data
    |
    Radiotron™